Cargando…

A Cocktail Interaction Study Evaluating the Drug‐Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels

ASP8477 (molecular weight 325.36 g/mol) is a fatty acid amide hydrolase inhibitor intended for the treatment of neuropathic pain. Results from in vitro studies indicated that ASP8477 is a direct inhibitor of cytochrome P450 (CYP) 2C8, 2C9, 2C19, 2D6, and 3A4 enzymes at expected efficacious concentra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treijtel, Nicoline, Collins, Christiane, van Bruijnsvoort, Michel, Fuhr, Rainard, Ernault, Etienne, Gangaram‐Panday, Shanti, Passier, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593727/ https://www.ncbi.nlm.nih.gov/pubmed/30730615 http://dx.doi.org/10.1002/cpdd.660

Ejemplares similares

Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug–drug interactions with different perpetrator drugs
por: Mikus, Gerd, et al.
Publicado: (2020)

A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling
por: de Jong, Laura M., et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects
por: Schaffler, Klaus, et al.
Publicado: (2018)

The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain
por: Bradford, Daniel, et al.
Publicado: (2017)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions
por: Wicha, Sebastian G., et al.
Publicado: (2017)

Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
por: Bleasby, Kelly, et al.
Publicado: (2021)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail
por: Rohr, Brit Silja, et al.
Publicado: (2021)

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
por: Jacobs, Tom G, et al.
Publicado: (2021)

Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions
por: Stopfer, Peter, et al.
Publicado: (2018)

In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions
por: Martin, Parthena, et al.
Publicado: (2022)

The drug cocktail network
por: Xu, Ke-Jia, et al.
Publicado: (2012)

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail
por: Bosilkovska, Marija, et al.
Publicado: (2019)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
por: Wang, Kun, et al.
Publicado: (2021)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
por: Zhu, Tong, et al.
Publicado: (2020)

Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential
por: Cataldi, Mauro, et al.
Publicado: (2023)

Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters
por: Barth, Aline, et al.
Publicado: (2023)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
por: Ngo, Lien Thi, et al.
Publicado: (2023)

Drug Cocktail Optimization in Chemotherapy of Cancer
por: Preissner, Saskia, et al.
Publicado: (2012)

The Development and Validation of a Novel “Dual Cocktail” Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions
por: Kwon, Mihwa, et al.
Publicado: (2020)

Clinical Drug–Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects
por: Ishii, Yasuyuki, et al.
Publicado: (2018)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2021)

Drug Cocktail Formulation via Circuit Design
por: Beahm, Douglas Raymond, et al.
Publicado: (2023)

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil
por: Rowland, Angela, et al.
Publicado: (2016)

Predicting Drug-Target Interactions Using Drug-Drug Interactions
por: Kim, Shinhyuk, et al.
Publicado: (2013)

A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators
por: Yang, Yiting, et al.
Publicado: (2021)

Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
por: Mulford, Darcy J., et al.
Publicado: (2023)

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
por: Bolhuis, Mathieu S., et al.
Publicado: (2011)

Direct conversion of astrocytes into neuronal cells by drug cocktail
por: Cheng, Lin, et al.
Publicado: (2015)

Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative
por: Bahar, Muh. Akbar, et al.
Publicado: (2020)

Drug-drug interactions in the ICU
por: Ray, S, et al.
Publicado: (2009)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Antiretroviral drug–drug interactions: A comparison of online drug interaction databases
por: Drwiega, Emily N., et al.
Publicado: (2022)

Pharmacokinetics of gallic acid and protocatechuic acid in humans after dosing with Relinqing (RLQ) and the potential for RLQ-perpetrated drug–drug interactions on organic anion transporter (OAT) 1/3
por: Li, Ziqiang, et al.
Publicado: (2021)

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions
por: Hahn, Martina, et al.
Publicado: (2021)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
por: Fuhr, Laura Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_evde12rpodrigpfur2d2umgsig